Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267696
Status:
COMPLETED
Last Update Posted:
2015-04-30
First Post:
2005-12-19
Brief Title:
Study of GemcitabineCarboplatinBevacizumab to Treat Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization:
Ohio State University Comprehensive Cancer Center
Study Overview
Official Title:
A Phase II Study of GemcitabineCarboplatinBevacizumab in Platinum Sensitive Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the effectiveness safety and tolerability of the drug combination gemcitabine carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer fallopian tube or primary peritoneal cancer
Detailed Description:
In this study participants will receive the drug combination gemcitabinecarboplatin and bevacizumab once every two weeks As long as there is evidence that the tumor is not growing and the participant is not experiencing any unacceptable side effects participation can continue up to 2 years The study is being done to find the effectiveness safety and tolerability of this combination of chemotherapy drugs Bevacizumab affects the growth of new blood vessels in the body It is part of this study to see if stopping the growth of new blood vessels in the body will help stop the growth and the spread of cancer The other two chemotherapy drugs gemcitabine and carboplatin are currently being used together for the treatment of ovarian cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None